Peter Koelblinger

13PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology not elsewhere classifiedMolecular targetsPredictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 26, 2026
The Value of Adjuvant Radiotherapy in the Treatment of Melanoma: A Multi-Center Analysis.

|Sep 02, 2026
Ropeginterferon-α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients.

|Jan 11, 2025
Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review.

Magdalena Hoellwerth, Matthias Brandlmaier, Peter Koelblinger

|Apr 27, 2024
Adjuvant PD-1 Checkpoint Inhibition in Early Cutaneous Melanoma: Immunological Mode of Action and the Role of Ultraviolet Radiation.

Matthias Brandlmaier, Magdalena Hoellwerth, Peter Koelblinger

|Jan 11, 2024
Prognostic Value of Baseline 18F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients.

Forough Kalantari, Seyed Ali Mirshahvalad, Magdalena Hoellwerth

|May 13, 2023
Impact of [18F]FDG PET/CT in the Assessment of Immunotherapy-Induced Arterial Wall Inflammation in Melanoma Patients Receiving Immune Checkpoint Inhibitors.

Shaghayegh Ranjbar, Seyed Rasoul Zakavi, Roya Eisazadeh

Pageof 3

Frequent Collaborators

5 joint publications

Matthias Brandlmaier

4 joint publications

Magdalena Hoellwerth

3 joint publications

Roland Lang

2 joint publications

Andrea Harrer